Market Insight – The promise of orexin antagonists
This article was originally published in Scrip
July's announcement of a $146 million-plus deal between GlaxoSmithKlineand the Swiss biopharmaceutical companyActelion, to collaborate on the development and commercialisation of orexin antagonist almorexant, has thrown the whole area of orexin research under the spotlight. Almorexant is in Phase III trials as a treatment for primary insomnia, but the potential applications of orexin antagonists extend beyond just the management of sleep disturbances.
You may also be interested in...
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
Asia life science-focused VC firms*
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.